[go: up one dir, main page]

IL137936A0 - 2-arylethyl- (piperidin-4-ylmethyl) amine derivatives as muscarinic receptor antagonists - Google Patents

2-arylethyl- (piperidin-4-ylmethyl) amine derivatives as muscarinic receptor antagonists

Info

Publication number
IL137936A0
IL137936A0 IL13793699A IL13793699A IL137936A0 IL 137936 A0 IL137936 A0 IL 137936A0 IL 13793699 A IL13793699 A IL 13793699A IL 13793699 A IL13793699 A IL 13793699A IL 137936 A0 IL137936 A0 IL 137936A0
Authority
IL
Israel
Prior art keywords
arylethyl
piperidin
ylmethyl
receptor antagonists
muscarinic receptor
Prior art date
Application number
IL13793699A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL137936A0 publication Critical patent/IL137936A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/08Mydriatics or cycloplegics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
IL13793699A 1998-02-27 1999-02-19 2-arylethyl- (piperidin-4-ylmethyl) amine derivatives as muscarinic receptor antagonists IL137936A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7611398P 1998-02-27 1998-02-27
US10909798P 1998-11-19 1998-11-19
PCT/EP1999/001102 WO1999043657A1 (en) 1998-02-27 1999-02-19 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives as muscarinic receptor antagonists

Publications (1)

Publication Number Publication Date
IL137936A0 true IL137936A0 (en) 2001-10-31

Family

ID=26757679

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13793699A IL137936A0 (en) 1998-02-27 1999-02-19 2-arylethyl- (piperidin-4-ylmethyl) amine derivatives as muscarinic receptor antagonists

Country Status (26)

Country Link
US (1) US6319920B1 (es)
EP (1) EP1058680B1 (es)
JP (1) JP3523198B2 (es)
KR (1) KR100384906B1 (es)
CN (1) CN1143848C (es)
AR (1) AR015523A1 (es)
AT (1) ATE400554T1 (es)
AU (1) AU753255B2 (es)
BR (1) BR9909253A (es)
CA (1) CA2321198C (es)
CO (1) CO4990939A1 (es)
DE (1) DE69939053D1 (es)
ES (1) ES2310032T3 (es)
HR (1) HRP20000544A2 (es)
HU (1) HUP0100760A3 (es)
IL (1) IL137936A0 (es)
MA (1) MA26610A1 (es)
MY (1) MY133445A (es)
NO (1) NO317106B1 (es)
NZ (1) NZ506317A (es)
PE (1) PE20000325A1 (es)
PL (1) PL194037B1 (es)
RU (1) RU2220138C2 (es)
TR (1) TR200002481T2 (es)
WO (1) WO1999043657A1 (es)
YU (1) YU53100A (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1012150A4 (en) * 1997-05-19 2002-05-29 Sugen Inc HETEROARYLCARBOXAMIDE COMPOUNDS THAT ARE EFFECTIVE OF DISEASES CAUSED BY PROTEIN-TYROSIN-KINASE
WO2001090082A1 (en) * 2000-05-25 2001-11-29 F. Hoffmann-La Roche Ag Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
JP4071000B2 (ja) 2000-05-25 2008-04-02 エフ.ホフマン−ラ ロシュ アーゲー 置換1−アミノアルキルラクタム及びムスカリン受容体アンタゴニストとしてのそれらの使用
CN100358870C (zh) 2001-12-03 2008-01-02 弗·哈夫曼-拉罗切有限公司 作为毒蕈碱受体拮抗剂的氨基四氢萘衍生物
PL370765A1 (en) 2001-12-03 2005-05-30 F.Hoffmann-La Roche Ag 4-piperidinyl alkylamine derivatives as muscarinic receptor antagonists
EP1552825A4 (en) * 2002-06-07 2009-11-25 Astellas Pharma Inc THERAPEUTIC AGENT FOR THE TREATMENT OF VESIC HYPERACTIVITY
DE60230683D1 (de) 2002-07-08 2009-02-12 Ranbaxy Lab Ltd 3,6-disubstituierte azabicyclo-3.1.0 hexan-derivat
TWI295669B (en) * 2002-10-30 2008-04-11 Theravance Inc Substituted 4-amino-1-(pyridylmethyl) piperidine and related compounds
CN100364990C (zh) * 2002-10-30 2008-01-30 施万制药 取代的4-氨基-1-(吡啶甲基)哌啶和相关化合物
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
ES2288641T3 (es) * 2002-12-20 2008-01-16 Dynogen Pharmaceuticals Inc. Metodo para tratar trastornos indoloros de la vejiga usando moduladores de canales del calcio de la subunidad alfa2-delta.
DE602004003172T2 (de) * 2003-03-21 2007-09-27 Dynogen Pharmaceuticals Inc., Waltham Verfahren zur behandlung von erkrankungen der unteren harnwege mit antimuskarinika und mit modulatoren der alpha-2-delta untereinheit des kalziumkanals
WO2004089898A1 (en) 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
US20070021487A1 (en) 2003-04-11 2007-01-25 Mohammad Salman Azabicyclo derivatives as muscarinic receptor antagonists
JP2007524641A (ja) * 2003-07-11 2007-08-30 セラヴァンス, インコーポレーテッド 置換4−アミノ−1−ベンジルピペリジン化合物
FR2861073B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
US7214439B2 (en) * 2003-12-19 2007-05-08 Millennium Cell, Inc. Triborohydride salts as hydrogen storage materials and preparation thereof
JP2010525058A (ja) 2007-04-24 2010-07-22 セラヴァンス, インコーポレーテッド ムスカリン受容体アンタゴニストとして有用な第4級アンモニウム化合物
DE102007020492A1 (de) * 2007-04-30 2008-11-06 Grünenthal GmbH Substituierte Sulfonamid-Derivate
EP3170807B1 (en) * 2015-11-23 2019-12-11 Frau Pharma S.r.l. New method for synthesis of fenfluramine
SI25272A (sl) 2016-09-23 2018-03-30 Univerza V Ljubljani Disubstituirani azetidini, pirolidini, piperidini in azepani kot zaviralci monoamin oksidaze B za zdravljenje nevrodegenerativnih bolezni
CN112824378A (zh) * 2019-11-20 2021-05-21 珠海润都制药股份有限公司 一种盐酸坦索罗辛的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0361791B1 (en) 1988-09-26 1995-11-08 Smithkline Beecham Farmaceutici S.p.A. Azacyclic derivatives useful as medicaments
SU1829346A1 (ru) * 1991-04-01 1996-01-10 Институт Тонкой Органической Химии Им.А.Л.Мнджояна ДИГИДРОХЛОРИДЫ N-[β-(1,2,5-ТРИМЕТИЛ-4-АРИЛПИПЕРИДИН-4-ИЛ)ЭТИЛ]-N-АЛКИЛ-N-(3,4-ДИМЕТОКСИБЕНЗИЛ)АМИНОВ, ЯВЛЯЮЩИЕСЯ ИНГИБИТОРАМИ КАЛЬЦИЙ-КАЛЬМОДУЛИНЗАВИСИМЫХ ПРОЦЕССОВ
MY110227A (en) 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
FR2681320B1 (fr) 1991-09-12 1994-01-14 Synthelabo Derives de n-(4,7dimethoxyindan-2-yl)-1-(phenylcarbonyl)-n-propyl-piperidine-4-methanamine, leur preparation et leur application en therapeutique.
FR2681325B1 (fr) 1991-09-16 1993-12-17 Fabre Medicament Pierre Derives de l'aminomethyl-4 piperidine, leur preparation et leur application en therapeutique.
EP0853615B1 (en) 1995-09-15 2003-12-10 Neurosearch A/S Piperidine compounds as calcium channel blockers
AU7145996A (en) * 1995-10-13 1997-04-30 Banyu Pharmaceutical Co., Ltd. Substituted heteroaromatic derivatives

Also Published As

Publication number Publication date
JP3523198B2 (ja) 2004-04-26
DE69939053D1 (de) 2008-08-21
MY133445A (en) 2007-11-30
AU753255B2 (en) 2002-10-10
MA26610A1 (fr) 2004-12-20
HUP0100760A2 (hu) 2001-08-28
WO1999043657A1 (en) 1999-09-02
HRP20000544A2 (en) 2001-02-28
EP1058680A1 (en) 2000-12-13
KR100384906B1 (ko) 2003-05-23
NO20004261D0 (no) 2000-08-25
TR200002481T2 (tr) 2000-11-21
NO20004261L (no) 2000-08-25
YU53100A (sh) 2003-04-30
AU2835399A (en) 1999-09-15
KR20010041321A (ko) 2001-05-15
CN1143848C (zh) 2004-03-31
CN1295563A (zh) 2001-05-16
HK1036623A1 (en) 2002-01-11
ATE400554T1 (de) 2008-07-15
EP1058680B1 (en) 2008-07-09
ES2310032T3 (es) 2008-12-16
CO4990939A1 (es) 2000-12-26
JP2002504543A (ja) 2002-02-12
PL342692A1 (en) 2001-07-02
CA2321198A1 (en) 1999-09-02
BR9909253A (pt) 2000-11-28
US6319920B1 (en) 2001-11-20
RU2220138C2 (ru) 2003-12-27
HUP0100760A3 (en) 2002-12-28
NO317106B1 (no) 2004-08-09
CA2321198C (en) 2009-11-17
NZ506317A (en) 2003-08-29
AR015523A1 (es) 2001-05-02
PL194037B1 (pl) 2007-04-30
PE20000325A1 (es) 2000-05-08

Similar Documents

Publication Publication Date Title
IL137936A0 (en) 2-arylethyl- (piperidin-4-ylmethyl) amine derivatives as muscarinic receptor antagonists
PL356034A1 (en) Cyclic amine compounds as ccr5 antagonists
IL143226A0 (en) Pyrrolidine derivatives-ccr-3 receptor antagonists
SG80041A1 (en) Muscarinic receptor antagonists
IL145742A0 (en) Piperidine derivatives useful as ccr5 antagonists
HUP0301665A3 (en) Novel benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists
PL356990A1 (en) Isoxazolecarboxamide derivatives as alpha1-adrenergic receptor antagonists
IL140249A0 (en) Muscarinic antagonists
EP1061921A4 (en) VITRONECTIN RECEPTOR ANTAGONIST
HRP970098B1 (en) Oxa- and thia-diazole muscarinic receptor antagonists
IL142045A0 (en) Naphthalenecarboxamides as tachykinin receptor antagonists
EP1248607A4 (en) UROTENSIN II RECEPTOR ANTAGONISTS
IL148043A0 (en) Novel integrin receptor antagonists
GR3034847T3 (en) Indoline derivatives useful as 5-ht-2c receptor antagonists
IL150272A0 (en) Indole derivatives as mcp-1 receptor antagonists
HUP9903439A3 (en) Indoline derivatives useful as 5-ht-2c receptor antagonists
AU1566499A (en) Imidazol derivatives as muscarinic m3 receptor antagonists
EP1102587A4 (en) vitronectin receptor antagonists
GB0026327D0 (en) Thrombin receptor antagonists
ZA200003475B (en) Muscarinic receptor antagonists.
GB9811283D0 (en) Vironectin receptor antagonists
GB9814737D0 (en) Fibrinogen receptor antagonists
ID25461A (id) Turunan 2-ariletil-(piperidin-4-ilmetil)amina sebagai antagonis reseptor muskarinik
SI0912556T1 (en) Indoline derivatives useful as 5-ht-2c receptor antagonists
GB9811295D0 (en) Vitronectin receptor antagonists